Cargando…
P991: IMPAIRMENT OF TCR SIGNALLING IN PATIENTS WITH MYELOFIBROSIS TREATED WITH RUXOLITINIB
Autores principales: | Harrington, P., Dillon, R., Radia, D., McLornan, D., Curto-Garcia, N., Woodley, C., Asirvatham, S., Kordasti, S., Harrison, C., de Lavallade, H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429637/ http://dx.doi.org/10.1097/01.HS9.0000846832.56792.11 |
Ejemplares similares
-
Low-dose Splenic Irradiation in Conjunction With Ruxolitinib to Provide Symptomatic Relief in Heavily Treated, Advanced Stage Myelofibrosis: A Case Series From a UK Tertiary Referral Center
por: Khan, Alesia, et al.
Publicado: (2021) -
Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T‐cell phenotype
por: Harrington, Patrick, et al.
Publicado: (2022) -
Impaired humoral and T cell response to vaccination against SARS-CoV-2 in chronic myeloproliferative neoplasm patients treated with ruxolitinib
por: Harrington, Patrick, et al.
Publicado: (2022) -
P990: T CELL RESPONSE AND OMICRON VARIANT NEUTRALISATION FOLLOWING VACCINATION AGAINST SARS-COV-2 IN PATIENTS WITH CHRONIC MYELOID DISORDERS
por: Harrington, P., et al.
Publicado: (2022) -
Ruxolitinib for the Treatment of Essential Thrombocythemia
por: Gunawan, Arief, et al.
Publicado: (2018)